Clinical Report: Cell-mediated antithrombotic properties of tranexamic acid
Overview
Tranexamic acid (TXA) significantly reduces the odds of venous thrombus formation without affecting thrombus mass or primary hemostasis.
Background
Tranexamic acid is widely used to manage bleeding in various clinical settings, including trauma and surgery. Its effects on thrombus formation and potential prothrombotic risks have raised questions regarding its prophylactic use. Understanding TXA's mechanisms, particularly its cell-mediated effects, is crucial.
Data Highlights
Outcome
Effect of TXA
Odds of venous thrombus formation
Reduced by 90%
Thrombus mass
No change
Thrombin generation in whole blood
Decreased
Primary hemostasis (tail bleeding)
No effect
Key Findings
TXA reduced the odds of venous thrombus formation by 90%.
TXA did not alter thrombus mass once clots were formed.
TXA suppressed the stenosis-induced rise in MCP-1.
TXA decreased thrombin generation in whole blood but not in platelet-rich plasma.
TXA inhibited leukocyte surface-mediated plasminogen activation within fibrin clots.
Primary hemostasis was unaffected by TXA.
Clinical Implications
The findings suggest that TXA can be safely used to reduce thrombus initiation without compromising primary hemostasis. Clinicians should consider the cellular context when administering TXA, particularly in settings where thrombus formation is a concern.
Conclusion
TXA demonstrates a cell-mediated antithrombotic effect by reducing thrombus initiation while maintaining hemostatic function. Further research may clarify its role in various clinical scenarios.
by Kata Balog Virág, Petra Csikós, Alexandra Raska, Barbara Baráth, Kristóf Molnár, Natalia Nikolova, Kiril Tenekedjiev, Krasimir Kolev, Nikolett Wohner
